D. Scott Wood
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
D. Scott Wood has a total of 5 co-authors. Here are the top co-authors by number of shared publications:
- Antoine Douaihy
University of Pittsburgh
1 shared publication - Dennis C. Daley
UPMC Health Plan, US Steel Tower, 600 Grant Street, Pittsburgh, PA 15219, USA
1 shared publication - Duncan B. Clark
University of Pittsburgh
1 shared publication - Jack R. Cornelius
University of Pittsburgh, Western Psychiatric Institute and Clinic, 3811 O'Hara Street, Pittsburgh, PA 15213, USA
1 shared publication - Tammy Chung
Department of Psychiatry, Robert Wood Johnson Medical School, Rutgers University; Institute for Health, Health Care Policy and Aging Research
1 shared publication
Latest Publications
- 1 July 2012
- Published by Taylor & Francis in Journal of Dual Diagnosis
- Vol. 8 (3) , 200-204
Mirtazapine in Comorbid Major Depression and Alcohol Dependence: An Open-Label Trial
Objective: This was a first pilot study evaluating the acute phase (8-week) efficacy of the antidepressant medication mirtazapine for the treatment of depressive symptoms and drinking of subjects with comorbid major depressive disorder and alcohol dependence (MDD/AD). We hypothesized that mirtazapine would demonstrate within-group efficacy for the treatment of both depressive symptoms and drinking in these subjects. Methods: We conducted a first open-label study of the second-generation antidepressant mirtazapine in 12 adult outpatient subjects with comorbid MDD/AD. The pharmacological profile of that medication is unique among antidepressants, unrelated to tricyclics or selective serotonin reuptake inhibitors. Results: Mirtazapine was well tolerated in this treatment population. Self-reported depressive symptoms decreased from 31.8 to 8.3 on the Beck Depression Inventory (BDI), a 74.0% decrease (p < .001), and drinking decreased from 33.9 to 13.3 drinks per week, a 60.8% decrease (p < .05). None of the subjects were employed full time at baseline, but 9 of the 12 (75%) were employed full time at the end the of study. Conclusions: These preliminary findings suggest efficacy for mirtazapine for treating both the depressive symptoms and excessive alcohol use of comorbid major depressive disorder and alcohol dependence. Double-blind studies are warranted to further clarify the efficacy of mirtazapine in this population.
- 1 July 2012
- Published by Taylor & Francis in Journal of Dual Diagnosis
- Vol. 8 (3) , 200-204
Mirtazapine in Comorbid Major Depression and Alcohol Dependence: An Open-Label Trial
Objective: This was a first pilot study evaluating the acute phase (8-week) efficacy of the antidepressant medication mirtazapine for the treatment of depressive symptoms and drinking of subjects with comorbid major depressive disorder and alcohol dependence (MDD/AD). We hypothesized that mirtazapine would demonstrate within-group efficacy for the treatment of both depressive symptoms and drinking in these subjects. Methods: We conducted a first open-label study of the second-generation antidepressant mirtazapine in 12 adult outpatient subjects with comorbid MDD/AD. The pharmacological profile of that medication is unique among antidepressants, unrelated to tricyclics or selective serotonin reuptake inhibitors. Results: Mirtazapine was well tolerated in this treatment population. Self-reported depressive symptoms decreased from 31.8 to 8.3 on the Beck Depression Inventory (BDI), a 74.0% decrease (p < .001), and drinking decreased from 33.9 to 13.3 drinks per week, a 60.8% decrease (p < .05). None of the subjects were employed full time at baseline, but 9 of the 12 (75%) were employed full time at the end the of study. Conclusions: These preliminary findings suggest efficacy for mirtazapine for treating both the depressive symptoms and excessive alcohol use of comorbid major depressive disorder and alcohol dependence. Double-blind studies are warranted to further clarify the efficacy of mirtazapine in this population.